About | Free Trial

Last Update

2016-03-28T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Wrong William Ludlam?

Dr. William Ludlam H.

Vice President, Medical Affairs

Chiasma Inc.

HQ Phone: (617) 378-7474

Email: w***@***.com

Chiasma Inc.

831 Beacon Street

Newton Centre, Massachusetts 02459

United States

Company Description

Chiasma is a biopharma company focused on creating new drug products by marrying its proprietary technology to approved drugs. This enables drugs to be switched from injectable to oral, but importantly can also result in new indications or improved labels ... more

Find other employees at this company (55)

Background Information

Employment History

Senior Medical Director
Novartis AG

Program Director
Swedish Medical Center

Doctor (Endocrinologist)
KOL Novartis acro

Education

M.D.

Web References (121 Total References)


William H. Ludlam , M.D., ...

ir.chiasmapharma.com [cached]

William H. Ludlam , M.D., Ph.D., as Vice President of Medical Affairs.

...
Dr. Ludlam came to Chiasma from Novartis Pharmaceuticals Corporation , where he served most recently as Senior Medical Director for


New additions to the team include ...

www.biospace.com [cached]

New additions to the team include Anand Varadan as Chief Commercial Officer and William H. Ludlam, M.D., Ph.D., as Vice President of Medical Affairs.

...
Dr. Ludlam came to Chiasma from Novartis Pharmaceuticals Corporation, where he served most recently as Senior Medical Director for U.S. Clinical Development and Medical Affairs, Pituitary Disorders, Rare Diseases Franchise.


Chiasma Appoints William ...

ir.chiasmapharma.com [cached]

Chiasma Appoints William H. Ludlam, M.D., Ph.D., as Vice President of Medical Affairs

...
William H. Ludlam
...
Dr. Ludlam, a highly-regarded academic leader in the pituitary and rare disease space, comes to Chiasma after spending the last four years at Novartis Pharmaceuticals , where he served most recently as Senior Medical Director for the U.S. Clinical Development and Medical Affairs (USCDMA), Pituitary Disorders, Rare Diseases Franchise. Novartis is currently a leading seller of injectable octreotide, one of the standard treatment options for patients suffering from acromegaly.
In his role at Chiasma, Dr. Ludlam will be responsible for developing strategy around clinical and technical information to support the planned commercial launch of Mycapssa™ for the maintenance treatment of adults with acromegaly. He will also lead all medical review activities around the Company's product education campaign, including its presence at key scientific events. In
...
"Dr. Ludlam's extensive academic and industry experience in the rare disease space, particularly pituitary disorders, makes him an ideal choice to help lead the medical strategy for our anticipated launch of Mycapssa™ in 2016," said
...
"Dr. Ludlam has worked firsthand with acromegaly patients, both in his current role at
...
in 2012, Dr. Ludlam spent 15 years in a number of academic and clinical roles. From 2007 to 2011, he served as medical director at the Seattle Pituitary Center within the Neuroscience Institute at the Swedish Medical Center , and from 2002 to 2006 as medical director of the Pituitary Unit at the Oregon Health and Science University . Dr. Ludlam helped develop both treatment centers and conducted clinical research for novel treatment options for pituitary disorders while actively treating patients with acromegaly and Cushing's disease, among other conditions.
Dr. Ludlam holds an M.D. and Ph.D. from the
...
"I am extremely pleased to be joining Chiasma prior to the potential launch of Mycapssa™," said Dr. Ludlam.


About Us | Hormone Health Network

www.hormone.org [cached]

William Ludlam, MD, PhD Novartis Pharmaceuticals


Chiasma Appoints William ...

ir.chiasmapharma.com [cached]

Chiasma Appoints William H. Ludlam, M.D., Ph.D., as Vice President of Medical Affairs

- Well-known pituitary expert to provide senior medical and technical leadership for Company's planned commercial launch of octreotide capsules (Mycapssa™) - NEWTON, Mass. and JERUSALEM, Israel, Aug. 24, 2015 /PRNewswire/ -- Chiasma, Inc. (NASDAQ: CHMA), a U.S. late-stage biopharmaceutical company developing Mycapssa™ (octreotide capsules) for the maintenance therapy of adult patients with acromegaly, today announced the appointment of William H. Ludlam, M.D., Ph.D., as vice president of me...

Similar Profiles

Other People with this Name

Other people with the name Ludlam

Fiona Ludlam
Southern Cross Cycle Club

Merrill Ludlam
Tualatin Valley Garden Club

Jennifer Ludlam
Criterion Systems, Inc.

Gina Ludlam
Chase Professionals

Angie Ludlam
Energy Solutions

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory